75 related articles for article (PubMed ID: 25017122)
1. Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.
Berghoff AS; Bartsch R; Preusser M; Ricken G; Steger GG; Bago-Horvath Z; Rudas M; Streubel B; Dubsky P; Gnant M; Fitzal F; Zielinski CC; Birner P
Breast; 2014 Oct; 23(5):637-43. PubMed ID: 25017122
[TBL] [Abstract][Full Text] [Related]
2. Survival analysis of patients with brain metastases at initial breast cancer diagnosis over the last decade.
Avila J; Leone J; Vallejo CT; Lin NU; Leone JP
Breast Cancer Res Treat; 2024 Jun; 205(3):579-587. PubMed ID: 38453783
[TBL] [Abstract][Full Text] [Related]
3. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer.
Da Silva L; Simpson PT; Smart CE; Cocciardi S; Waddell N; Lane A; Morrison BJ; Vargas AC; Healey S; Beesley J; Pakkiri P; Parry S; Kurniawan N; Reid L; Keith P; Faria P; Pereira E; Skalova A; Bilous M; Balleine RL; Do H; Dobrovic A; Fox S; Franco M; Reynolds B; Khanna KK; Cummings M; Chenevix-Trench G; Lakhani SR
Breast Cancer Res; 2010; 12(4):R46. PubMed ID: 20604919
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors.
Jácome AA; Wohnrath DR; Scapulatempo Neto C; Carneseca EC; Serrano SV; Viana LS; Nunes JS; Martinez EZ; Santos JS
Gastric Cancer; 2014 Jan; 17(1):76-86. PubMed ID: 23455716
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of the patients with metastatic male breast cancer.
Dogan I; Khanmammadov N; Ozkurt S; Aydiner A; Saip P
J Cancer Res Ther; 2024 Jan; 20(1):98-102. PubMed ID: 38554305
[TBL] [Abstract][Full Text] [Related]
6. Self-inhibition of HER2 and HER3 at fever temperatures may prevent their hetero-dimerization.
Singh PK; Stan RC
J Biomol Struct Dyn; 2024 Jul; 42(10):5470-5473. PubMed ID: 37342980
[TBL] [Abstract][Full Text] [Related]
7. Why does HER2-positive breast cancer metastasize to the brain and what can we do about it?
Xu D; Hu Z; Wang K; Hu S; Zhou Y; Zhang S; Chen Y; Pan T
Crit Rev Oncol Hematol; 2024 Mar; 195():104269. PubMed ID: 38272149
[TBL] [Abstract][Full Text] [Related]
8. Survival Analysis of Male Patients with Brain Metastases at Initial Breast Cancer Diagnosis over the Last Decade.
Avila J; Leone J; Vallejo CT; Leone JP
Med Sci (Basel); 2024 Mar; 12(1):. PubMed ID: 38535156
[TBL] [Abstract][Full Text] [Related]
9. Quantitative proteomic analysis of HER2 protein expression in PDAC tumors.
Randall J; Hunt AL; Nutcharoen A; Johnston L; Chouraichi S; Wang H; Winer A; Wadlow R; Huynh J; Davis J; Corgiat B; Bateman NW; Deeken JF; Petricoin EF; Conrads TP; Cannon TL
Clin Proteomics; 2024 Mar; 21(1):24. PubMed ID: 38509475
[TBL] [Abstract][Full Text] [Related]
10. A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.
Dey N; Williams C; Leyland-Jones B; De P
Am J Transl Res; 2015; 7(4):733-50. PubMed ID: 26064441
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody.
Meneses-Lorente G; Friess T; Kolm I; Hölzlwimmer G; Bader S; Meille C; Thomas M; Bossenmaier B
Cancer Chemother Pharmacol; 2015 Apr; 75(4):837-50. PubMed ID: 25702049
[TBL] [Abstract][Full Text] [Related]
12. Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases.
Berghoff AS; Ilhan-Mutlu A; Dinhof C; Magerle M; Hackl M; Widhalm G; Hainfellner JA; Dieckmann K; Pichler J; Hutterer M; Melchardt T; Bartsch R; Zielinski CC; Birner P; Preusser M
Neuropathol Appl Neurobiol; 2015 Feb; 41(2):e41-55. PubMed ID: 25256708
[TBL] [Abstract][Full Text] [Related]
13. HER3 in cancer: from the bench to the bedside.
Gandullo-Sánchez L; Ocaña A; Pandiella A
J Exp Clin Cancer Res; 2022 Oct; 41(1):310. PubMed ID: 36271429
[TBL] [Abstract][Full Text] [Related]
14. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.
Hanker AB; Brown BP; Meiler J; Marín A; Jayanthan HS; Ye D; Lin CC; Akamatsu H; Lee KM; Chatterjee S; Sudhan DR; Servetto A; Brewer MR; Koch JP; Sheehan JH; He J; Lalani AS; Arteaga CL
Cancer Cell; 2021 Aug; 39(8):1099-1114.e8. PubMed ID: 34171264
[TBL] [Abstract][Full Text] [Related]
15. A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer.
Zong HF; Li X; Han L; Wang L; Liu JJ; Yue YL; Chen J; Ke Y; Jiang H; Xie YQ; Zhang BH; Zhu JW
Acta Pharmacol Sin; 2024 Apr; ():. PubMed ID: 38605180
[TBL] [Abstract][Full Text] [Related]
16. Overcoming brain-derived therapeutic resistance in HER2+ breast cancer brain metastasis.
Ippolitov D; Lin YH; Spence J; Glogowska A; Thanasupawat T; Beiko J; Del Bigio MR; Xu X; Wang A; Calvo R; Kapoor A; Marugan JJ; Henderson MJ; Klonisch T; Hombach-Klonisch S
bioRxiv; 2024 Feb; ():. PubMed ID: 38529509
[TBL] [Abstract][Full Text] [Related]
17. Quantitative systems pharmacology modeling of HER2-positive metastatic breast cancer for translational efficacy evaluation and combination assessment across therapeutic modalities.
Zhou YT; Chu JH; Zhao SH; Li GL; Fu ZY; Zhang SJ; Gao XH; Ma W; Shen K; Gao Y; Li W; Yin YM; Zhao C
Acta Pharmacol Sin; 2024 Feb; ():. PubMed ID: 38360930
[TBL] [Abstract][Full Text] [Related]
18. Navigating the Blood-Brain Barrier: Challenges and Therapeutic Strategies in Breast Cancer Brain Metastases.
Terceiro LEL; Ikeogu NM; Lima MF; Edechi CA; Nickel BE; Fischer G; Leygue E; McManus KJ; Myal Y
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569410
[TBL] [Abstract][Full Text] [Related]
19. HER3 Alterations in Cancer and Potential Clinical Implications.
Kilroy MK; Park S; Feroz W; Patel H; Mishra R; Alanazi S; Garrett JT
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551663
[TBL] [Abstract][Full Text] [Related]
20. PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening.
Lee J; Liu H; Pearson T; Iwase T; Fuson J; Lalani AS; Eli LD; Diala I; Tripathy D; Lim B; Ueno NT
Biomedicines; 2021 Jun; 9(7):. PubMed ID: 34203351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
